MAPT and Alzheimer disease: While there are several evidences for the presence of Aβ and phosphotau in eyes from human and animal AD paradigms, efforts are currently being made to identify and validate additional post-translational modifications of tau occurring in the neurosensory retina during disease progression, especially in view of the findings that tau better correlates with the duration and the severity of cognitive decline [49, 50].